November 2, 2024 Tech Titans’ Mixed Results Stall Wall Street Bull Run
October 28, 2024 Recent Oil Slides In Global Markets, Japan In Flux
Microsoft: The Party Is Coming To An End
Apple Q4: Further Risk To Near-Term China Estimate?
Apple: Berkshire Sales And Slow Revenue Raise Concerns
AMZN: Wall Street’s Most Loved Stock May Be A Growth Trap
October 22, 2024 A Comprehensive Guide to RoadRunner Auto Transport Services
October 3, 2024 Mastering Trading Indicators: Your Essential Toolkit For Success
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
April 12, 2024 Improve Your Financial Status: A How-To Guide
BioCryst Pharmaceuticals (BCRX) stock forecast for 2024
Updated: November 6, 2024 (07:27)
Sector: HealthcareThe share price of BioCryst Pharmaceuticals, Inc. (BCRX) now
50/200 Day Moving Average: $7.84 / $6.42
This figure corresponds to the Average Price over the previous 50/200 days. For BioCryst Pharmaceuticals stocks, the 50-day moving average is the resistance level today.
For BioCryst Pharmaceuticals stocks, the 200-day moving average is the resistance level today.
Are you interested in BioCryst Pharmaceuticals, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the BioCryst Pharmaceuticals stock price in 2024. How much will one BioCryst Pharmaceuticals share be worth in 2024? Is it worth taking profit / loss on BCRX stock now or waiting? What are analysts' forecasts for BioCryst Pharmaceuticals stock?
We forecast BioCryst Pharmaceuticals stock performance using neural networks based on historical data on BCRX stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account. This corporation stock prediction results are shown below and presented as a graph, table and text information.
BioCryst Pharmaceuticals, Inc. stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for BioCryst Pharmaceuticals analysts is $14.64. Today 200 Day Moving Average is the support level (6.42 $). 50 Day Moving Average is the support level (7.84 $).
Historical and forecast chart of BioCryst Pharmaceuticals, Inc. stock
The chart below shows the historical price of BioCryst Pharmaceuticals stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the BCRX stock price can be found in the table below.
BioCryst Pharmaceuticals, Inc., a biotech company, is dedicated to the discovery of oral and small molecule drugs. The company markets injections of peramivir, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza, under the names RAPIVAB, ALPIVAB, RAPIACTA and PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for the treatment of peripheral T-cell lymphoma.
BioCryst Pharmaceuticals (BCRX) Forecast for 2024
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Dec | 7.17 | 6.63 | 7.53 | 11.89 % |
BioCryst Pharmaceuticals information and performance
4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC, US
Market capitalization of the BioCryst Pharmaceuticals, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of BCRX shares in the company outstanding by the market price of one share.
EBITDA of BioCryst Pharmaceuticals is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
BioCryst Pharmaceuticals price target for 2024 by month
Target values for the price of one BioCryst Pharmaceuticals share for Dec 2024.
In Dec, the Positive dynamics for BioCryst Pharmaceuticals, Inc. shares will prevail with possible monthly volatility of 11.895% volatility is expected.
Pessimistic target level: 6.63
Optimistic target level: 7.53
Related stocks from Healthcare sector